Online inquiry

IVTScrip™ mRNA-Anti-pcrV, BA1126(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3476MR)

This product GTTS-WQ3476MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets pcrV gene. The antibody can be applied in Pseudomonas aeruginosa infections research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq WP_003100789.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
UniProt ID O30527
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-pcrV, BA1126(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ3476MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ639MR IVTScrip™ mRNA-Anti-AOC3, 8c10(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 8c10
GTTS-WQ9377MR IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA Interleukin 2
GTTS-WQ14507MR IVTScrip™ mRNA-Anti-IL6R, SA-237(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA SA-237
GTTS-WQ13742MR IVTScrip™ mRNA-Anti-ANGPTL3, REGN 1500(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA REGN 1500
GTTS-WQ1309MR IVTScrip™ mRNA-Anti-MET, ABT-700(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABT-700
GTTS-WQ10682MR IVTScrip™ mRNA-Anti-TNFSF13B, LymphoStat-B(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LymphoStat-B
GTTS-WQ11961MR IVTScrip™ mRNA-Anti-LTA, MLTA3698A(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MLTA3698A
GTTS-WQ15870MR IVTScrip™ mRNA-Anti-CD19, XmAb5871(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA XmAb5871
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW